Safety and tolerability of RJx-01 to maintain muscle integrity in patients following hospitalisation with an acute exacerbation of COPD (MINT-COPD): protocol for a phase IIa randomised double-blind placebo-controlled trial
- 1Institute for Lung Health, NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK
Abstract
Introduction Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of global disability and disability-adjusted life years. One of the key systemic features of COPD is impaired skeletal muscle mass and function, termed sarcopenia. The recognition of skeletal muscle dysfunction as a treatable trait in COPD opens a therapeutic avenue for pharmacological development, with the aim of improving physical function and reducing healthcare utilisation. A novel combination drug, RJx-01, was identified as a candidate therapy for sarcopenia based on preclinical evidence. The primary aim of this study is to evaluate the safety and tolerability of RJx-01 compared with placebo following hospitalisation with an acute exacerbation of COPD (AECOPD), when acute deterioration of skeletal muscle integrity is observed. Exploratory efficacy analyses will assess differences in muscle function, mass, and multi-omic-derived outcomes. Methods and analysis The MINT-COPD trial is a phase IIa, single centre, randomised controlled trial (RCT). Eighty participants admitted to hospital with AECOPD will be randomly assigned 1:1 to receive either oral RJx-01 or placebo, once daily for 24 weeks. The primary outcome is safety and tolerability of RJx-01 compared with placebo in COPD patients. Exploratory objectives aim to assess the preliminary effects of AECOPD-associated hospitalisation and RJx-01 treatment on muscle mass, function, and fatiguability, as well as patient reported symptoms and frailty. The optional skeletal muscle biopsy sub-study aims to assess the effects of AECOPD on proteomic and transcriptomic markers of skeletal muscle.
Related
- High-flow nasal oxygen versus non-invasive ventilation in patients with acute hypercapnic exacerbation of COPD: a systematic review and meta-analysis of randomised controlled trials
- Efficacy and tolerability of D-β-hydroxybutyrate ester in patients with amyotrophic lateral sclerosis (KETO-ALS)–a randomised, placebo-controlled, double-blind study
- The Effect of Medication Self-Management During Hospitalisation (SelfMED) on Medication Adherence Post-Discharge in Oncology Patients with Polypharmacy: A Prospective, Exploratory, Single-Centre, Non-Randomised Pre-Post Intervention Study with Sequential Control and Intervention Cohorts.
- A Phase I, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of intravenous ertapenem and zidebactam in combination (WCK 6777) in healthy adult subjects
- Short-term safety and local tolerability of repeated exposure to aerosolized hypochlorous acid dry fog in healthy adults: a randomized controlled pilot study
BibTeX
@misc{qureshi2026safety,
title = {{Safety and tolerability of RJx-01 to maintain muscle integrity in patients following hospitalisation with an acute exacerbation of COPD (MINT-COPD): protocol for a phase IIa randomised double-blind placebo-controlled trial}},
author = {I. N. Qureshi and G. Mills and H. J. C. McAuley and L. Latimer and L. Meuleners and L. Haazen and L. Baker and P. Ashley and N. Sathyanarayana and E. Oladipupo and J. Clanchy and A. C. Ugarte and S. Verheijden and A. Beliën and J. Aerssens and N. J. Greening},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.06.26367435},
url = {https://www.medrxiv.org/content/10.64898/2026.11.06.26367435v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Safety and tolerability of RJx-01 to maintain muscle integrity in patients following hospitalisation with an acute exacerbation of COPD (MINT-COPD): protocol for a phase IIa randomised double-blind placebo-controlled trial
AU - I. N. Qureshi
AU - G. Mills
AU - H. J. C. McAuley
AU - L. Latimer
AU - L. Meuleners
AU - L. Haazen
AU - L. Baker
AU - P. Ashley
AU - N. Sathyanarayana
AU - E. Oladipupo
AU - J. Clanchy
AU - A. C. Ugarte
AU - S. Verheijden
AU - A. Beliën
AU - J. Aerssens
AU - N. J. Greening
PY - 2026
DA - 2026/11/06
PB - medRxiv
DO - 10.64898/2026.11.06.26367435
UR - https://www.medrxiv.org/content/10.64898/2026.11.06.26367435v1
AB - Introduction Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of global disability and disability-adjusted life years. One of the key systemic features of COPD is impaired skeletal muscle mass and function, termed sarcopenia. The recognition of skeletal muscle dysfunction as a treatable trait in COPD opens a therapeutic avenue for pharmacological development, with the aim of improving physical function and reducing healthcare utilisation. A novel combination drug, RJx-01, was identified as a candidate therapy for sarcopenia based on preclinical evidence. The primary aim of this study is to evaluate the safety and tolerability of RJx-01 compared with placebo following hospitalisation with an acute exacerbation of COPD (AECOPD), when acute deterioration of skeletal muscle integrity is observed. Exploratory efficacy analyses will assess differences in muscle function, mass, and multi-omic-derived outcomes. Methods and analysis The MINT-COPD trial is a phase IIa, single centre, randomised controlled trial (RCT). Eighty participants admitted to hospital with AECOPD will be randomly assigned 1:1 to receive either oral RJx-01 or placebo, once daily for 24 weeks. The primary outcome is safety and tolerability of RJx-01 compared with placebo in COPD patients. Exploratory objectives aim to assess the preliminary effects of AECOPD-associated hospitalisation and RJx-01 treatment on muscle mass, function, and fatiguability, as well as patient reported symptoms and frailty. The optional skeletal muscle biopsy sub-study aims to assess the effects of AECOPD on proteomic and transcriptomic markers of skeletal muscle.
ER -